Symbols / RVTY Stock $99.30 +0.35% Revvity, Inc.

Healthcare • Diagnostics & Research • United States • NYQ
RVTY (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Dr. Prahlad R. Singh Ph.D.
Exch · Country NYQ · United States
Market Cap 11.10B
Enterprise Value 13.60B
Income 239.11M
Sales 2.90B
FCF (ttm) 507.51M
Book/sh 64.20
Cash/sh 7.69
Employees 11,000
Insider 10d —
IPO Feb 21, 1973
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 13.49%
P/E 47.74
Forward P/E 17.09
PEG 0.62
P/S 3.83
P/B 1.55
P/C —
EV/EBITDA 15.95
EV/Sales 4.68
Quick Ratio 1.25
Current Ratio 1.72
Debt/Eq 46.64
LT Debt/Eq —
EPS (ttm) 2.08
EPS next Y 5.81
EPS Growth 3.50%
Revenue Growth 7.00%
EPS Gr Q/Q -3.60%
Rev Gr Q/Q —
Earnings (next) 2026-07-27
Earnings (prior) 2026-05-05
ROA 2.26%
ROE 3.23%
ROIC —
Gross Margin 54.32%
Oper. Margin 12.22%
Profit Margin 8.26%
Shs Outstand 111.80M
Shs Float 102.72M
Insider Own 0.34%
Instit Own 103.58%
Short Float 11.22%
Short Ratio 9.53
Short Interest 8.38M
52W High 118.30
vs 52W High -16.06%
52W Low 81.22
vs 52W Low 22.26%
Beta 1.05
Impl. Vol. 65.80%
Rel Volume 0.86
Avg Volume 1.19M
Volume 1.02M
Target (mean) $113.64
Tgt Median $110.00
Tgt Low $90.00
Tgt High $145.00
# Analysts 14
Recom Buy
Prev Close $98.95
Price $99.30
Change 0.35%
About

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$113.64
Mean price target
2. Current target
$99.30
Latest analyst target
3. DCF / Fair value
$81.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$99.30
Low
$90.00
High
$145.00
Mean
$113.64

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main Barclays Equal-Weight → Equal-Weight $105
2026-05-06 main JP Morgan Neutral → Neutral $90
2026-05-06 main TD Cowen Buy → Buy $120
2026-05-06 main Stifel Hold → Hold $100
2026-05-04 main Baird Outperform → Outperform $125
2026-04-14 main Goldman Sachs Neutral → Neutral $95
2026-04-14 down Barclays Overweight → Equal-Weight $95
2026-03-31 main JP Morgan Neutral → Neutral $96
2026-02-03 main JP Morgan Neutral → Neutral $105
2026-02-03 main TD Cowen Buy → Buy $124
2026-02-03 main Evercore ISI Group Outperform → Outperform $118
2026-02-03 main Wells Fargo Equal-Weight → Equal-Weight $110
2026-02-03 main Barclays Overweight → Overweight $118
2026-02-03 main Jefferies Hold → Hold $105
2025-12-15 main Barclays Overweight → Overweight $115
2025-12-15 main Wells Fargo Equal-Weight → Equal-Weight $107
2025-12-09 init Goldman Sachs — → Neutral $105
2025-10-28 main Barclays Overweight → Overweight $105
2025-10-28 main Baird Outperform → Outperform $123
2025-10-16 init Guggenheim — → Neutral —
News
RSS: Latest RVTY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-20 GONZALES ANITA Officer — 80 $92.80 $7,424
2026-03-16 GONZALES ANITA Officer — 1,600 $0.00 $0
2026-03-06 GONZALES ANITA Officer — 1,721 $0.00 $0
2026-02-24 VICTOR MIRIAME Officer — 1,862 $95.74 $178,268
2026-02-24 VICTOR MIRIAME Officer — 1,862 $97.13 $180,856
2026-02-23 MCMURRY-HEATH MICHELLE Director — 600 $97.26 $58,356
2026-02-05 SINGH PRAHLAD R Chief Executive Officer — 25,525 $92.09 $2,350,597
2026-02-05 GOLDBERG JOEL S General Counsel — 12,717 $92.09 $1,171,109
2026-02-05 GOLDBERG JOEL S General Counsel — 12,717 $99.47 $1,274,357
2026-02-05 SINGH PRAHLAD R Chief Executive Officer — 25,525 $99.02 $2,557,859
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2,856.05
+3.67%
2,755.03
+0.16%
2,750.57
-16.95%
3,311.82
Operating Revenue
2,856.05
+3.67%
2,755.03
+0.16%
2,750.57
-16.95%
3,311.82
Cost Of Revenue
1,291.69
+6.10%
1,217.37
+0.54%
1,210.88
-8.40%
1,321.99
Reconciled Cost Of Revenue
1,291.69
+6.10%
1,217.37
+0.54%
1,210.88
-8.40%
1,321.99
Gross Profit
1,564.37
+1.74%
1,537.66
-0.13%
1,539.69
-22.62%
1,989.83
Operating Expense
1,207.73
+1.41%
1,190.92
-3.89%
1,239.13
-0.64%
1,247.13
Research And Development
215.84
+9.65%
196.84
-9.11%
216.58
-2.27%
221.62
Selling General And Administration
991.89
-0.22%
994.07
-2.78%
1,022.55
-0.29%
1,025.51
Total Expenses
2,499.42
+3.78%
2,408.28
-1.70%
2,450.01
-4.64%
2,569.12
Operating Income
356.63
+2.85%
346.74
+15.36%
300.56
-59.53%
742.70
Total Operating Income As Reported
356.63
+2.85%
346.74
+15.36%
300.56
-59.53%
742.70
EBITDA
765.80
-8.86%
840.25
+17.76%
713.56
-39.67%
1,182.79
Normalized EBITDA
792.21
-5.61%
839.27
+6.85%
785.46
-34.90%
1,206.45
Reconciled Depreciation
405.34
-5.26%
427.85
-0.91%
431.77
+1.12%
427.00
EBIT
360.46
-12.59%
412.40
+46.35%
281.79
-62.72%
755.79
Total Unusual Items
-26.41
-2791.64%
0.98
+101.36%
-71.90
-203.96%
-23.65
Total Unusual Items Excluding Goodwill
-26.41
-2791.64%
0.98
+101.36%
-71.90
-203.96%
-23.65
Special Income Charges
—
—
—
—
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
241.20
-10.79%
270.38
-60.99%
693.09
+21.77%
569.18
Pretax Income
268.28
-15.14%
316.13
+72.77%
182.98
-71.93%
651.84
Net Non Operating Interest Income Expense
-61.08
-164.56%
-23.09
+13.47%
-26.68
+73.42%
-100.37
Interest Expense Non Operating
92.19
-4.25%
96.28
-2.57%
98.81
-4.95%
103.95
Net Interest Income
-61.08
-164.56%
-23.09
+13.47%
-26.68
+73.42%
-100.37
Interest Expense
92.19
-4.25%
96.28
-2.57%
98.81
-4.95%
103.95
Interest Income Non Operating
31.10
-57.50%
73.19
+1.47%
72.13
+1909.78%
3.59
Interest Income
31.10
-57.50%
73.19
+1.47%
72.13
+1909.78%
3.59
Other Income Expense
-27.28
-262.38%
-7.53
+91.72%
-90.90
-1056.48%
9.50
Other Non Operating Income Expenses
-0.87
+89.76%
-8.51
+55.24%
-19.01
-157.32%
33.16
Gain On Sale Of Security
-26.41
-2791.64%
0.98
+101.36%
-71.90
-203.96%
-23.65
Tax Provision
28.39
-14.10%
33.05
+851.77%
3.47
-97.50%
139.16
Tax Rate For Calcs
0.00
+0.95%
0.00
+452.63%
0.00
-91.10%
0.00
Tax Effect Of Unusual Items
-2.80
-2817.28%
0.10
+107.54%
-1.37
+72.95%
-5.05
Net Income Including Noncontrolling Interests
241.20
-10.79%
270.38
-60.99%
693.09
+21.77%
569.18
Net Income From Continuing Operation Net Minority Interest
239.88
-15.26%
283.07
+57.70%
179.50
-64.99%
512.68
Net Income From Continuing And Discontinued Operation
241.20
-10.79%
270.38
-60.99%
693.09
+21.77%
569.18
Net Income Continuous Operations
239.88
-15.26%
283.07
+57.70%
179.50
-64.99%
512.68
Net Income Discontinuous Operations
1.32
+110.39%
-12.69
-102.47%
513.59
+808.96%
56.50
Normalized Income
263.49
-6.63%
282.19
+12.86%
250.03
-52.94%
531.28
Net Income Common Stockholders
241.20
-10.79%
270.38
-60.99%
693.09
+21.77%
569.18
Diluted EPS
2.07
-5.91%
2.20
-60.36%
5.55
+21.18%
4.58
Basic EPS
2.07
-7.64%
2.24
-60.09%
5.62
+22.47%
4.59
Basic Average Shares
116.54
-3.40%
120.65
-2.25%
123.43
-2.28%
126.30
Diluted Average Shares
116.59
-5.07%
122.82
-1.59%
124.81
-1.28%
126.43
Diluted NI Availto Com Stockholders
241.20
-10.79%
270.38
-60.99%
693.09
+21.77%
569.18
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
12,168.41
-1.81%
12,392.48
-8.64%
13,564.67
-4.00%
14,129.85
Current Assets
2,239.75
-4.68%
2,349.61
-21.71%
3,001.09
-8.74%
3,288.56
Cash Cash Equivalents And Short Term Investments
919.86
-20.93%
1,163.40
-27.43%
1,603.08
+252.82%
454.36
Cash And Cash Equivalents
919.86
-20.93%
1,163.40
+27.40%
913.16
+100.98%
454.36
Other Short Term Investments
—
0.00
-100.00%
689.92
0.00
Receivables
744.67
+17.75%
632.40
-0.06%
632.81
+3.27%
612.78
Accounts Receivable
744.67
+17.75%
632.40
-0.06%
632.81
+3.27%
612.78
Inventory
379.50
+3.24%
367.59
-14.13%
428.06
+5.57%
405.46
Raw Materials
173.03
-0.84%
174.50
-11.54%
197.27
+3.48%
190.64
Work In Process
68.98
+5.82%
65.19
-5.76%
69.18
+1.42%
68.21
Finished Goods
137.48
+7.50%
127.89
-20.87%
161.62
+10.23%
146.62
Assets Held For Sale Current
—
—
0.00
-100.00%
1,693.70
Other Current Assets
195.72
+5.10%
186.22
-44.76%
337.14
+175.77%
122.25
Total Non Current Assets
9,928.66
-1.14%
10,042.87
-4.93%
10,563.57
-2.56%
10,841.30
Net PPE
644.69
-0.81%
649.93
-2.23%
664.74
-0.98%
671.30
Gross PPE
1,258.57
+9.48%
1,149.60
+1.00%
1,138.22
+8.87%
1,045.49
Accumulated Depreciation
-613.88
-22.86%
-499.67
-5.53%
-473.49
-26.53%
-374.19
Properties
0.00
0.00
0.00
0.00
Land And Improvements
33.02
+11.84%
29.52
-0.38%
29.64
+4.57%
28.34
Buildings And Improvements
391.10
+7.28%
364.56
+1.72%
358.38
+3.53%
346.16
Machinery Furniture Equipment
669.02
+13.82%
587.81
-1.23%
595.12
+23.31%
482.64
Other Properties
165.44
-1.36%
167.72
+8.15%
155.08
-17.66%
188.35
Goodwill And Other Intangible Assets
8,960.50
-1.58%
9,104.54
-4.72%
9,555.87
-3.07%
9,858.94
Goodwill
6,613.49
+2.32%
6,463.62
-1.07%
6,533.55
+0.80%
6,481.77
Other Intangible Assets
2,347.00
-11.13%
2,640.92
-12.62%
3,022.32
-10.51%
3,377.17
Other Non Current Assets
323.48
+12.16%
288.40
-15.91%
342.97
+10.26%
311.05
Total Liabilities Net Minority Interest
4,918.05
+4.07%
4,725.60
-16.98%
5,691.93
-15.64%
6,746.98
Current Liabilities
1,331.25
+103.83%
653.10
-54.97%
1,450.46
-6.09%
1,544.48
Payables And Accrued Expenses
504.06
+13.30%
444.88
-13.92%
516.85
-11.19%
581.96
Payables
266.03
+9.99%
241.87
-17.25%
292.28
-8.22%
318.45
Accounts Payable
185.46
+10.75%
167.46
-17.96%
204.12
-25.18%
272.83
Current Accrued Expenses
238.03
+17.25%
203.01
-9.60%
224.57
-14.78%
263.51
Pensionand Other Post Retirement Benefit Plans Current
48.13
+8.93%
44.18
+2.09%
43.28
-16.74%
51.98
Total Tax Payable
80.56
+8.28%
74.40
-15.60%
88.16
+93.23%
45.62
Income Tax Payable
80.56
+8.28%
74.40
-15.60%
88.16
+93.23%
45.62
Current Debt And Capital Lease Obligation
618.86
+2497.65%
23.82
-96.84%
754.78
+50.31%
502.15
Current Debt
588.83
+243217.36%
0.24
-99.97%
721.87
+53.29%
470.93
Other Current Borrowings
588.83
+243217.36%
0.24
-99.97%
721.87
+53.29%
470.93
Current Capital Lease Obligation
30.04
+27.36%
23.58
-28.34%
32.91
+5.41%
31.22
Current Deferred Liabilities
160.19
+14.25%
140.21
+3.44%
135.56
+0.02%
135.53
Current Deferred Revenue
160.19
+14.25%
140.21
+3.44%
135.56
+0.02%
135.53
Other Current Liabilities
—
—
—
272.87
Total Non Current Liabilities Net Minority Interest
3,586.80
-11.93%
4,072.50
-3.98%
4,241.46
-18.47%
5,202.50
Liabilities Heldfor Sale Non Current
—
—
—
0.00
Long Term Debt And Capital Lease Obligation
2,779.34
-15.83%
3,301.98
-0.26%
3,310.52
-19.12%
4,093.32
Long Term Debt
2,631.24
-16.48%
3,150.48
-0.86%
3,177.77
-19.00%
3,923.35
Long Term Capital Lease Obligation
148.11
-2.24%
151.50
+14.13%
132.75
-21.90%
169.97
Non Current Deferred Liabilities
—
—
—
1,109.18
Non Current Deferred Taxes Liabilities
—
—
—
1,109.18
Other Non Current Liabilities
807.46
+4.79%
770.52
-17.23%
930.95
-16.07%
1,109.18
Stockholders Equity
7,250.36
-5.43%
7,666.87
-2.61%
7,872.74
+6.64%
7,382.88
Common Stock Equity
7,250.36
-5.43%
7,666.87
-2.61%
7,872.74
+6.64%
7,382.88
Capital Stock
112.28
-6.93%
120.65
-2.25%
123.43
-2.28%
126.30
Common Stock
112.28
-6.93%
120.65
-2.25%
123.43
-2.28%
126.30
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
112.28
-6.93%
120.65
-2.25%
123.43
-2.28%
126.30
Ordinary Shares Number
112.28
-6.93%
120.65
-2.25%
123.43
-2.28%
126.30
Additional Paid In Capital
1,305.90
-37.73%
2,097.11
-13.23%
2,416.79
-12.21%
2,753.05
Retained Earnings
6,054.31
+3.58%
5,845.22
+4.21%
5,609.21
+13.29%
4,951.02
Gains Losses Not Affecting Retained Earnings
-222.13
+43.92%
-396.11
-43.16%
-276.69
+38.17%
-447.50
Other Equity Adjustments
-222.13
+43.92%
-396.11
-43.16%
-276.69
+38.17%
-447.50
Total Equity Gross Minority Interest
7,250.36
-5.43%
7,666.87
-2.61%
7,872.74
+6.64%
7,382.88
Total Capitalization
9,881.60
-8.65%
10,817.35
-2.11%
11,050.51
-2.26%
11,306.22
Working Capital
908.50
-46.45%
1,696.51
+9.41%
1,550.63
-11.09%
1,744.08
Invested Capital
10,470.42
-3.21%
10,817.59
-8.11%
11,772.38
-0.04%
11,777.15
Total Debt
3,398.21
+2.18%
3,325.80
-18.19%
4,065.30
-11.54%
4,595.46
Net Debt
2,300.20
+15.74%
1,987.32
-33.46%
2,986.48
-24.20%
3,939.92
Capital Lease Obligations
178.14
+1.75%
175.09
+5.70%
165.65
-17.66%
201.19
Net Tangible Assets
-1,710.14
-18.95%
-1,437.67
+14.58%
-1,683.13
+32.02%
-2,476.07
Tangible Book Value
-1,710.14
-18.95%
-1,437.67
+14.58%
-1,683.13
+32.02%
-2,476.07
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
582.93
-7.22%
628.30
+588.38%
91.27
-86.57%
679.81
Cash Flow From Continuing Operating Activities
588.96
-11.43%
664.96
+138.00%
279.39
-58.46%
672.50
Cash From Discontinued Operating Activities
-6.02
+83.57%
-36.66
+80.51%
-188.12
-2673.39%
7.31
Net Income From Continuing Operations
239.88
-15.26%
283.07
+57.70%
179.50
-64.99%
512.68
Depreciation Amortization Depletion
405.34
-5.26%
427.85
-0.91%
431.77
+1.12%
427.00
Depreciation
—
68.50
+2.70%
66.70
+18.26%
56.40
Amortization Cash Flow
—
359.40
-1.56%
365.10
-1.48%
370.60
Depreciation And Amortization
405.34
-5.26%
427.85
-0.91%
431.77
+1.12%
427.00
Amortization Of Intangibles
—
359.40
-1.56%
365.10
-1.48%
370.60
Other Non Cash Items
59.08
+172.80%
21.66
-43.18%
38.12
-41.18%
64.80
Pension And Employee Benefit Expense
3.64
-61.21%
9.38
-59.37%
23.09
+199.94%
-23.10
Stock Based Compensation
22.85
-39.57%
37.81
-8.70%
41.41
-19.62%
51.52
Asset Impairment Charge
4.78
-79.03%
22.81
0.00
0.00
Deferred Tax
-61.57
+44.18%
-110.31
-13.16%
-97.48
+9.24%
-107.41
Deferred Income Tax
-61.57
+44.18%
-110.31
-13.16%
-97.48
+9.24%
-107.41
Operating Gains Losses
3.91
-52.99%
8.32
-80.87%
43.49
+250.65%
-28.87
Unrealized Gain Loss On Investment Securities
11.46
+243.96%
-7.96
-123.46%
33.92
+115.32%
15.75
Net Foreign Currency Exchange Gain Loss
0.27
+125.78%
-1.06
-104.40%
24.09
0.00
Change In Working Capital
-96.78
-428.71%
-18.30
+95.32%
-391.35
-48.82%
-262.97
Change In Receivables
-101.02
-532.62%
-15.97
-77.49%
-9.00
-113.61%
66.09
Changes In Account Receivables
-101.02
-532.62%
-15.97
-77.49%
-9.00
-113.61%
66.09
Change In Inventory
14.78
-67.21%
45.09
+419.55%
-14.11
+70.99%
-48.63
Change In Payables And Accrued Expense
-10.54
+77.77%
-47.42
+87.12%
-368.24
-31.31%
-280.43
Change In Accrued Expense
-17.89
+16.41%
-21.40
+92.67%
-291.81
-23.32%
-236.62
Change In Payable
7.34
+128.22%
-26.02
+65.95%
-76.43
-74.47%
-43.80
Change In Account Payable
7.34
+128.22%
-26.02
+65.95%
-76.43
-74.47%
-43.80
Investing Cash Flow
-17.35
-102.24%
776.16
-40.91%
1,313.52
+1088.72%
-132.85
Cash Flow From Continuing Investing Activities
-73.60
-111.89%
619.26
+181.35%
-761.21
-550.96%
-116.94
Cash From Discontinued Investing Activities
56.25
-64.15%
156.90
-92.44%
2,074.73
+13136.34%
-15.91
Capital Expenditure
-73.52
+15.15%
-86.65
-6.49%
-81.37
+4.98%
-85.63
Capital Expenditure Reported
-73.52
+15.15%
-86.65
-6.49%
-81.37
+4.98%
-85.63
Net Investment Purchase And Sale
-0.08
-100.01%
705.91
+204.15%
-677.76
-1670.01%
-38.29
Purchase Of Investment
-0.39
+94.16%
-6.59
+99.46%
-1,227.91
-2502.55%
-47.18
Sale Of Investment
0.30
-99.96%
712.50
+29.51%
550.15
+6088.45%
8.89
Net Business Purchase And Sale
0.00
0.00
+100.00%
-2.09
-129.86%
6.99
Purchase Of Business
0.00
0.00
+100.00%
-2.09
+72.25%
-7.52
Gain Loss On Sale Of Business
—
0.00
0.00
+100.00%
-2.89
Net Intangibles Purchase And Sale
—
—
—
—
Purchase Of Intangibles
—
—
—
—
Net Other Investing Changes
—
—
—
8.89
Financing Cash Flow
-857.52
+23.99%
-1,128.23
-19.12%
-947.12
-43.11%
-661.80
Cash Flow From Continuing Financing Activities
-857.52
+23.99%
-1,128.23
-19.12%
-947.12
-43.11%
-661.80
Net Issuance Payments Of Debt
-0.52
+99.93%
-723.07
-39.73%
-517.49
+7.45%
-559.17
Issuance Of Debt
—
0.00
-100.00%
6.32
-97.37%
240.00
Repayment Of Debt
-0.52
+99.93%
-723.07
-38.04%
-523.81
+34.46%
-799.17
Long Term Debt Issuance
—
0.00
-100.00%
6.32
-97.37%
240.00
Long Term Debt Payments
-0.52
+99.93%
-723.07
-38.04%
-523.81
+34.46%
-799.17
Net Long Term Debt Issuance
-0.52
+99.93%
-723.07
-39.73%
-517.49
+7.45%
-559.17
Short Term Debt Payments
—
—
—
-1.29
Net Short Term Debt Issuance
—
—
6.32
+589.40%
-1.29
Net Common Stock Issuance
-820.82
-122.10%
-369.58
+4.96%
-388.88
-382.26%
-80.64
Common Stock Payments
-820.82
-122.10%
-369.58
+4.96%
-388.88
-382.26%
-80.64
Common Stock Dividend Paid
-32.80
+4.80%
-34.45
+1.46%
-34.97
+1.07%
-35.34
Cash Dividends Paid
-32.80
+4.80%
-34.45
+1.46%
-34.97
+1.07%
-35.34
Repurchase Of Capital Stock
-820.82
-122.10%
-369.58
+4.96%
-388.88
-382.26%
-80.64
Proceeds From Stock Option Exercised
2.92
-62.02%
7.70
+77.28%
4.34
-69.22%
14.11
Net Other Financing Charges
-6.31
+28.53%
-8.83
+12.83%
-10.13
-1220.99%
-0.77
Changes In Cash
-291.94
-205.69%
276.23
-39.65%
457.68
+498.52%
-114.84
Effect Of Exchange Rate Changes
48.52
+285.57%
-26.15
-86.13%
-14.05
+58.37%
-33.75
Beginning Cash Position
1,164.45
+27.35%
914.37
+94.24%
470.75
-23.99%
619.34
End Cash Position
921.03
-20.90%
1,164.45
+27.35%
914.37
+94.24%
470.75
Free Cash Flow
509.41
-5.95%
541.65
+5369.01%
9.90
-98.33%
594.18
Interest Paid Supplemental Data
86.19
-5.38%
91.09
-3.10%
94.01
-4.01%
97.93
Income Tax Paid Supplemental Data
131.35
-15.19%
154.88
-56.95%
359.80
+11.37%
323.08
Common Stock Issuance
—
—
—
14.11
Issuance Of Capital Stock
—
—
—
14.11
Sale Of Business
—
0.00
-100.00%
0.15
-98.95%
14.51
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category